PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Pozycja w akcjach #1419
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Cena akcji
$37.84
Kapitalizacja rynkowa
$15.65B
Zmiana (1 dzień)
-4.42%
Zmiana (1 rok)
149.23%
Kraj
TW
Handel PharmaEssentia Corporation (6446)

Kategoria

Healthcare
Historia dywidend dla PharmaEssentia Corporation (6446)
PharmaEssentia Corporation (symbol giełdowy: 6446) wypłaciła łącznie 1 dywidend.
Suma wszystkich dywidend (skorygowana o podziały akcji): $0.99
Wskaźnik dywidendy (TTM): 0.0012
Wypłaty dywidend dla PharmaEssentia Corporation (6446) od 2025 do 2026
Roczne wypłaty dywidend
Rok Dywidenda (skorygowana o podziały akcji) Zmień
2026 (TTM) $0.9898 0.00%
2025 $0.9898 0.00%
Lista wszystkich wypłat dywidend
Rok Dywidenda Zmień
2026 (TTM) $1.10 0.00%
2025 $1.10 0.00%
Wypłaty dywidend firm podobnych lub konkurencyjnych